Manting Zeng

Mar 12, 2024 | onlinelibrary.wiley.com | Kun Liu |Youwen Zhu |Hong Zhu |Manting Zeng

1 INTRODUCTION Lung cancer is the deadliest and second most common form of cancer in the USA, with approximately 238,340 diagnoses and 127,070 deaths forecast in 2023 alone.1 Non-small cell lung cancer (NSCLC) patients comprise 85% of the lung cancer patient population, and roughly 70% of these patients are initially diagnosed only when the disease is locally advances or metastatic, exhibiting a 5-year overall survival (OS) rate of just 26%.2, 3 Only one in four NSCLC patients are eligible...